九典制药
(300705)
| 流通市值：37.36亿 | | | 总市值：50.53亿 |
| 流通股本：3.70亿 | | | 总股本：5.00亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,048,723,120.08 | 1,286,839,471.27 | 595,244,012.8 | 3,110,900,254.23 |
| 营业收入 | 2,048,723,120.08 | 1,286,839,471.27 | 595,244,012.8 | 3,110,900,254.23 |
| 二、营业总成本 | 1,777,471,633.03 | 1,119,470,663.56 | 540,618,256.72 | 2,579,938,093.88 |
| 营业成本 | 781,666,403.25 | 459,893,639.81 | 197,350,304.42 | 841,683,507.07 |
| 税金及附加 | 24,094,868.35 | 14,898,451.39 | 7,548,072.72 | 36,793,852.15 |
| 销售费用 | 690,643,770.06 | 446,960,193.7 | 240,255,334.09 | 1,305,742,567 |
| 管理费用 | 141,311,930.2 | 105,918,923.1 | 54,701,336.59 | 164,525,622.72 |
| 研发费用 | 116,520,279.79 | 77,194,833.68 | 34,194,794.02 | 218,409,582.01 |
| 财务费用 | 23,234,381.38 | 14,604,621.88 | 6,568,414.88 | 12,782,962.93 |
| 其中:利息费用 | 23,479,174.68 | 14,865,791.96 | 6,638,372.45 | 14,994,107.28 |
| 其中:利息收入 | 1,153,578.97 | 843,196.03 | 270,575.27 | 2,464,617.62 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -1,718,034.13 | -1,271,533.91 | -445,930.62 | -955,602.86 |
| 资产处置收益 | -41,603.71 | -57,604.93 | 0 | 50,728.92 |
| 资产减值损失(新) | -8,768,767.48 | -1,357,908.89 | -1,806,873.86 | -30,849,329.66 |
| 信用减值损失(新) | 5,397,435.16 | 252,119.41 | 33,862.47 | -905,610.14 |
| 其他收益 | 23,893,779.54 | 16,202,996.96 | 8,696,397.34 | 39,440,115.5 |
| 四、营业利润 | 290,014,296.43 | 181,136,876.35 | 61,103,211.41 | 537,742,462.11 |
| 加:营业外收入 | 688,743.44 | 363,476.43 | 458,596.55 | 2,106,576.26 |
| 减:营业外支出 | 10,066,204.62 | 1,863,458.76 | 533,298.75 | 13,488,039.16 |
| 五、利润总额 | 280,636,835.25 | 179,636,894.02 | 61,028,509.21 | 526,360,999.21 |
| 减:所得税费用 | 49,743,800.92 | 24,526,879.58 | 6,766,246.81 | 56,325,565.77 |
| 六、净利润 | 230,893,034.33 | 155,110,014.44 | 54,262,262.4 | 470,035,433.44 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 230,893,034.33 | 155,110,014.44 | 54,262,262.4 | 470,035,433.44 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 239,905,389.81 | 159,665,191.18 | 56,736,098.14 | 472,818,048.51 |
| 少数股东损益 | -9,012,355.48 | -4,555,176.74 | -2,473,835.74 | -2,782,615.07 |
| 扣除非经常损益后的净利润 | 229,832,177.55 | 149,041,332.97 | 50,597,232.2 | 453,129,305.84 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.49 | 0.4 | 0.11 | 0.96 |
| (二)稀释每股收益 | 0.49 | 0.4 | 0.11 | 0.95 |
| 九、综合收益总额 | 230,893,034.33 | 155,110,014.44 | 54,262,262.4 | 470,035,433.44 |
| 归属于母公司股东的综合收益总额 | 239,905,389.81 | 159,665,191.18 | 56,736,098.14 | 472,818,048.51 |
| 归属于少数股东的综合收益总额 | -9,012,355.48 | -4,555,176.74 | -2,473,835.74 | -2,782,615.07 |
| 公告日期 | 2026-10-29 | 2026-08-22 | 2026-04-25 | 2026-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |